BioXcel Therapeutics Reveals Expanded Market Opportunity for IGALMI At-Home Use

summarizeSummary

BioXcel Therapeutics announced an updated market opportunity assessment for IGALMI for at-home use, revealing an expanded addressable market and strong interest from prescribers and payers.

check_boxKey Events

• Expanded Market Opportunity for IGALMI

  An updated market assessment for IGALMI for acute agitation in the at-home setting identified up to 1.8 million eligible patients and 86 million addressable annual episodes, an increase from prior estimates of 57-77 million episodes.

• Strong Prescriber and Payer Interest

  Market research indicates prescribers project IGALMI use in approximately 70% of their schizophrenia and bipolar disorder patients, with payers expecting broad formulary coverage.

• Addresses Unmet Need

  Prescribers reported a moderate to high unmet need for at-home agitation treatments, noting current options are often not indicated for home use, may be sedating, slow-acting, or controlled substances.

• Follows sNDA Submission

  This positive market assessment follows the company's sNDA submission last month (January 20, 2026) seeking FDA approval for IGALMI's at-home use.

auto_awesomeAnalysis

This filing provides a highly positive market opportunity assessment for IGALMI's potential at-home use, following the supplemental New Drug Application (sNDA) submission on January 20, 2026. For a micro-cap company like BioXcel Therapeutics, which has previously disclosed 'going concern' risks, demonstrating an expanded and robust market for a key product is critical for future revenue generation and financial stability. The increased estimate of addressable annual episodes and strong prescriber/payer interest suggest a significant commercial runway if FDA approval is granted, potentially alleviating some financial pressures and boosting investor confidence in the product's commercial viability.